Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 145828, 11 pages
http://dx.doi.org/10.1155/2015/145828
Review Article

Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System

1Department of Clinical and Experimental Medicine, University of Messina, Via Faranda, 2-98123 Messina, Italy
2Department of Biomedical Sciences and Morphological and Functional Imaging, University of Messina, Italy
3Comenius University, Bratislava, Slovakia
4University Hospital (CHUV), Lausanne, Switzerland
5Second University of Naples, Naples, Italy

Received 28 November 2014; Revised 30 January 2015; Accepted 4 February 2015

Academic Editor: Ronald L. Klein

Copyright © 2015 Domenico Santoro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. H. Jafar, P. C. Stark, C. H. Schmid et al., “Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis,” Annals of Internal Medicine, vol. 139, no. 4, pp. 244–252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. F. M. Strippoli, M. Craig, F. P. Schena, and J. C. Craig, “Antihypertensive agents for primary prevention of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 3081–3091, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. L. F. Fried, N. Emanuele, J. H. Zhang et al., “Combined angiotensin inhibition for the treatment of diabetic nephropathy,” The New England Journal of Medicine, vol. 369, no. 20, pp. 1892–1903, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. A. H. J. Danser, “The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?” Hypertension Research, vol. 33, no. 1, pp. 4–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. C. Li, “Renoprotective effects of vitamin D analogs,” Kidney International, vol. 78, no. 2, pp. 134–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, and C. L. Yan, “Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 41, pp. 15896–15901, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Lenz, S. J. Elliot, and W. G. Stetler-Stevenson, “Matrix metalloproteinases in renal development and disease,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 574–581, 2000. View at Google Scholar · View at Scopus
  9. D. Santoro, D. Caccamo, G. Gagliostro et al., “Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients,” Journal of Nephrology, vol. 26, no. 4, pp. 636–644, 2013. View at Google Scholar · View at Scopus
  10. W. Jelkmann, “Molecular biology of erythropoietin,” Internal Medicine, vol. 43, no. 8, pp. 649–659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. C. Li, “Vitamin D regulation of the renin-angiotensin system,” Journal of Cellular Biochemistry, vol. 88, no. 2, pp. 327–331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. N. M. Patel, O. M. Gutiérrez, D. L. Andress, D. W. Coyne, A. Levin, and M. Wolf, “Vitamin D deficiency and anemia in early chronic kidney disease,” Kidney International, vol. 77, no. 8, pp. 715–720, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Agarwal, “Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?” Kidney International, vol. 77, no. 11, pp. 943–945, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Lucisano, E. di Mauro, G. Montalto, V. Cernaro, M. Buemi, and D. Santoro, “Vitamin D and anemia,” Journal of Renal Nutrition, vol. 24, no. 1, pp. 61–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Albitar, R. Genin, M. Fen-Chong, M.-O. Serveaux, D. Schohn, and C. Chuet, “High-dose alfacalcidol improves anaemia in patients on haemodialysis,” Nephrology Dialysis Transplantation, vol. 12, no. 3, pp. 514–518, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Saab, D. O. Young, Y. Gincherman, K. Giles, K. Norwood, and D. W. Coyne, “Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients,” Nephron—Clinical Practice, vol. 105, no. 3, pp. c132–c138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. P. T. Lac, K. Choi, I.-A. Liu, S. Meguerditchian, S. A. Rasgon, and J. J. Sim, “The effects of changing vitamin D levels on anemia in chronic kidney disease patients: a retrospective cohort review,” Clinical Nephrology, vol. 74, no. 1, pp. 25–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. J. Sim, P. T. Lac, I. L. A. Liu et al., “Vitamin D deficiency and anemia: a cross-sectional study,” Annals of Hematology, vol. 89, no. 5, pp. 447–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Zittermann, A. Jungvogel, S. Prokop et al., “Vitamin D deficiency is an independent predictor of anemia in end-stage heart failure,” Clinical Research in Cardiology, vol. 100, no. 9, pp. 781–788, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Chutia, A. A. Ruram, H. Bhattacharyya, P. Boruah, and C. Nath, “Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease,” Journal of Laboratory Physicians, vol. 5, no. 1, pp. 51–54, 2013. View at Publisher · View at Google Scholar
  21. M. Gallieni, C. Corsi, and D. Brancaccio, “Hyperparathyroidism and anemia in renal failure,” The American Journal of Nephrology, vol. 20, no. 2, pp. 89–96, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-G. Wu, F.-R. Jeng, S.-Y. Wei et al., “Red blood cell osmotic fragility in chronically hemodialyzed patients,” Nephron, vol. 78, no. 1, pp. 28–32, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Joy, P. C. Karagiannis, and F. W. Peyerl, “Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment,” Journal of Managed Care Pharmacy, vol. 13, no. 5, pp. 397–411, 2007. View at Google Scholar · View at Scopus
  24. A. Icardi, E. Paoletti, L. de Nicola, S. Mazzaferro, R. Russo, and M. Cozzolino, “Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation,” Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1672–1679, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Blazsek, C. Farabos, P. Quittet et al., “Bone marrow stromal cell defects and 1 alpha, 25-dihydroxyvitamin D3 deficiency underlying human myeloid leukemias,” Cancer Detection and Prevention, vol. 20, no. 1, pp. 31–42, 1996. View at Google Scholar · View at Scopus
  26. S. M. Zughaier, J. A. Alvarez, J. H. Sloan, R. J. Konrad, and V. Tangpricha, “The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes,” Journal of Clinical and Translational Endocrinology, vol. 1, no. 1, pp. e19–e25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Reichel, H. P. Koeffler, and A. W. Normal, “The role of the vitamin D endocrine system in health and disease,” The New England Journal of Medicine, vol. 320, no. 15, pp. 980–991, 1989. View at Publisher · View at Google Scholar · View at Scopus
  28. A. W. Norman, “Minireview: Vitamin D receptor: new assignments for an already busy receptor,” Endocrinology, vol. 147, no. 12, pp. 5542–5548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Aucella, R. P. Scalzulli, G. Gatta, M. Vigilante, A. M. Carella, and C. Stallone, “Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo,” Nephron. Clinical Practice, vol. 95, no. 4, pp. c121–c127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Santoro, L. Gitto, A. Ferraro, E. Satta, V. Savica, and G. Bellinghieri, “Vitamin D status and mortality risk in patients with chronic kidney disease,” Renal Failure, vol. 33, no. 2, Article ID 553303, pp. 184–191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. P. A. Marsden, D. M. Dorfman, T. Collins, B. M. Brenner, S. H. Orkin, and B. J. Ballermann, “Regulated expression of endothelin 1 in glomerular capillary endothelial cells,” The American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 261, no. 1, pp. F117–F125, 1991. View at Google Scholar · View at Scopus
  32. E. D. Burgess, R. G. Hawkins, and M. Watanabe, “Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension,” The American Journal of Hypertension, vol. 3, no. 12, pp. 903–905, 1990. View at Google Scholar · View at Scopus
  33. L. M. Resnick, F. B. Muller, and J. H. Laragh, “Calcium-regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism,” Annals of Internal Medicine, vol. 105, no. 5, pp. 649–654, 1986. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Tomaschitz, S. Pilz, E. Ritz et al., “Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study,” Clinica Chimica Acta, vol. 411, no. 17-18, pp. 1354–1360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. Forman, J. S. Williams, and N. D. L. Fisher, “Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans,” Hypertension, vol. 55, no. 5, pp. 1283–1288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. C. W. Park, Y. S. Oh, Y. S. Shin et al., “Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism,” The American Journal of Kidney Diseases, vol. 33, no. 1, pp. 73–81, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. C. Li, J. Kong, M. Wei, Z.-F. Chen, S. Q. Liu, and L.-P. Cao, “1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system,” Journal of Clinical Investigation, vol. 110, no. 2, pp. 229–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Kong, G. Qiao, Z. Zhang, S. Q. Liu, and Y. C. Li, “Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium,” Kidney International, vol. 74, no. 12, pp. 1577–1581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Yuan, W. Pan, J. Kong et al., “1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter,” Journal of Biological Chemistry, vol. 282, no. 41, pp. 29821–29830, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Freundlich, Y. Quiroz, Z. Zhang et al., “Suppression of renin-angiotensin gene expression in the kidney by paricalcitol,” Kidney International, vol. 74, no. 11, pp. 1394–1402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. R. M. Fryer, P. A. Rakestraw, M. Nakane et al., “Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice,” Nephron—Physiology, vol. 106, no. 4, pp. p76–p81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. S. S. Fischer, D. S. Kempe, C. B. Leibrock et al., “Hyperaldosteronism in klotho-deficient mice,” The American Journal of Physiology—Renal Physiology, vol. 299, no. 5, pp. F1171–F1177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. D. W. Good, T. George, and B. A. Watts III, “Aldosterone potentiates 1,25-dihydroxyvitamin D3 action in renal thick ascending limb via a nongenomic, ERK-dependent pathway,” The American Journal of Physiology—Cell Physiology, vol. 285, no. 5, pp. C1122–C1130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Xiang, J. Kong, S. Chen et al., “Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 1, pp. E125–E132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Thadhani, E. Appelbaum, Y. Pritchett et al., “Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial,” Journal of the American Medical Association, vol. 307, no. 7, pp. 674–684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Y.-M. Wang, F. Fang, J. Chan et al., “Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial,” Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 175–186, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Tamez, C. Zoccali, D. Packham et al., “Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease,” American Heart Journal, vol. 164, no. 6, pp. 902–909, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Jha, G. Garcia-Garcia, K. Iseki et al., “Chronic kidney disease: global dimension and perspectives,” The Lancet, vol. 382, no. 9888, pp. 260–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. B. K. Mahmoodi, K. Matsushita, M. Woodward et al., “Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis,” The Lancet, vol. 380, no. 9854, pp. 1649–1661, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. C. S. Fox, K. Matsushita, M. Woodward et al., “Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis,” The Lancet, vol. 380, pp. 1662–1673, 2012. View at Publisher · View at Google Scholar
  51. T. C. Turin, M. James, P. Ravani et al., “Proteinuria and rate of change in kidney function in a community-based population,” Journal of the American Society of Nephrology, vol. 24, no. 10, pp. 1661–1667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. L. de Nicola, P. Chiodini, C. Zoccali et al., “Prognosis of CKD patients receiving outpatient nephrology care in Italy,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2421–2428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. L. de Nicola, R. Minutolo, P. Chiodini et al., “The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care,” Kidney International, vol. 82, no. 4, pp. 482–488, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group, “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease,” Kidney International Supplements, vol. 3, no. 1, pp. 1–150, 2013. View at Google Scholar
  55. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al., “Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy,” Circulation, vol. 110, no. 8, pp. 921–927, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. W. B. A. Eijkelkamp, Z. Zhang, G. Remuzzi et al., “Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1540–1546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. R. E. Schmieder, J. F. E. Mann, H. Schumacher et al., “Changes in albuminuria predict mortality and morbidity in patients with vascular disease,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1353–1364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. A. S. Levey, D. Cattran, A. Friedman et al., “Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration,” American Journal of Kidney Diseases, vol. 54, no. 2, pp. 205–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Wolf and E. Ritz, “Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications,” Kidney International, vol. 67, no. 3, pp. 799–812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. F. Catapano, P. Chiodini, L. de Nicola et al., “Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and meta-regression,” The American Journal of Kidney Diseases, vol. 52, no. 3, pp. 475–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. M.-D. Sanchez-Niño, M. Bozic, E. Córdoba-Lanús et al., “Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 6, pp. F647–F657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. S. M. Sprague, F. Llach, M. Amdahl, C. Taccetta, and D. Batlle, “Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism,” Kidney International, vol. 63, no. 4, pp. 1483–1490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. M. J. Kim, A. H. Frankel, M. Donaldson et al., “Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin- aldosterone system inhibition,” Kidney International, vol. 80, no. 8, pp. 851–860, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. L.-J. Liu, J.-C. Lv, S.-F. Shi, Y.-Q. Chen, H. Zhang, and H.-Y. Wang, “Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial,” American Journal of Kidney Diseases, vol. 59, no. 1, pp. 67–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Agarwal, M. Acharya, J. Tian et al., “Antiproteinuric effect of oral paricalcitol in chronic kidney disease,” Kidney International, vol. 68, no. 6, pp. 2823–2828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Alborzi, N. A. Patel, C. Peterson et al., “Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial,” Hypertension, vol. 52, no. 2, pp. 211–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Fishbane, H. Chittineni, M. Packman, P. Dutka, N. Ali, and N. Durie, “Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial,” The American Journal of Kidney Diseases, vol. 54, no. 4, pp. 647–652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. D. de Zeeuw, R. Agarwal, M. Amdahl et al., “Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial,” The Lancet, vol. 376, no. 9752, pp. 1543–1551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Pisani, M. Sabbatini, G. Duro, P. Colomba, and E. Riccio, “Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study,” Nephrology Dialysis Transplantation, 2014. View at Publisher · View at Google Scholar
  70. J. Cheng, W. Zhang, X. Zhang, X. Li, and J. Chen, “Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis,” Clinical Journal of the American Society of Nephrology, vol. 7, pp. 391–400, 2012. View at Publisher · View at Google Scholar
  71. M. H. de Borst, R. Hajhosseiny, H. Tamez, J. Wenger, R. Thadhani, and D. J. A. Goldsmith, “Active vitamin D treatment for reduction of residual proteinuria: a systematic review,” Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1863–1871, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. F. L. Nauta, S. J. L. Bakker, W. van Oeveren et al., “Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients,” The American Journal of Kidney Diseases, vol. 57, no. 5, pp. 733–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Gonzalez, J. Rojas-Rivera, N. Polanco et al., “Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients,” Transplantation, vol. 95, no. 7, pp. e49–e52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Trillini, M. Cortinovis, P. Ruggenenti et al., “Paricalcitol for secondary hyperparathyroidism in renal transplantation,” Journal of the American Society of Nephrology, 2014. View at Publisher · View at Google Scholar
  75. M. D. Witham, M. A. Nadir, and A. D. Struthers, “Effect of vitamin D on blood pressure: a systematic review and meta-analysis,” Journal of Hypertension, vol. 27, no. 10, pp. 1948–1954, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. G. Pittas, M. Chung, T. Trikalinos et al., “Systematic review: vitamin D and cardiometabolic outcomes,” Annals of Internal Medicine, vol. 152, no. 5, pp. 307–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Tamez and R. I. Thadhani, “Vitamin D and hypertension: an update and review,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 5, pp. 492–499, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Şeker, M. Gür, G. Yüksel Kalkan et al., “Serum 25-hydroxyvitamin D level and extent and complexity of coronary artery disease,” Journal of Clinical Laboratory Analysis, vol. 28, no. 1, pp. 52–58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Scragg, M. Sowers, and C. Bell, “Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey,” American Journal of Hypertension, vol. 20, no. 7, pp. 713–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. J. P. Forman, E. Giovannucci, M. D. Holmes et al., “Plasma 25-hydroxyvitamin D levels and risk of incident hypertension,” Hypertension, vol. 49, no. 5, pp. 1063–1069, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. C. Li, G. Qiao, M. Uskokovic, W. Xiang, W. Zheng, and J. Kong, “Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure,” Journal of Steroid Biochemistry and Molecular Biology, vol. 89-90, no. 1–5, pp. 387–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. S. E. Judd, S. N. Raiser, M. Kumari, and V. Tangpricha, “1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: A Pilot Seasibility Study,” Journal of Steroid Biochemistry and Molecular Biology, vol. 121, no. 1-2, pp. 445–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Bernini, D. Carrara, A. Bacca et al., “Effect of acute and chronic vitamin D administration on systemic renin angiotensin systemin essential hypertensives and controls,” Journal of Endocrinological Investigation, vol. 36, no. 4, pp. 216–220, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Carrara, M. Bernini, A. Bacca et al., “Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D,” Journal of Renin-Angiotensin-Aldosterone System, vol. 15, no. 1, pp. 82–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Abdi-Ali, D. D. M. Nicholl, B. R. Hemmelgarn, J. M. MacRae, D. Y. Sola, and S. B. Ahmed, “25-Hydroxyvitamin D status, arterial stiffness and the renin-angiotensin system in healthy humans,” Clinical and Experimental Hypertension, vol. 36, no. 6, pp. 386–391, 2014. View at Publisher · View at Google Scholar
  86. M. Pfeifer, B. Begerow, H. W. Minne, D. Nachtigall, and C. Hansen, “Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1633–1637, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. J. A. Sugden, J. I. Davies, M. D. Witham, A. D. Morris, and A. D. Struthers, “Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels,” Diabetic Medicine, vol. 25, no. 3, pp. 320–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. O. Tarcin, D. G. Yavuz, B. Ozben et al., “Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 10, pp. 4023–4030, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Dong, I. S. Stallmann-Jorgensen, N. K. Pollock et al., “A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-Hydroxyvitamin D, adiposity, and arterial stiffness,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4584–4591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. M. B. Elamin, N. O. Abu Elnour, K. B. Elamin et al., “Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 1931–1942, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Arora, Y. Song, J. Dusek et al., “Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial,” Circulation, vol. 131, no. 3, pp. 254–262, 2015. View at Publisher · View at Google Scholar
  92. M. D. Witham, S. Ireland, J. Graeme Houston et al., “Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial,” Hypertension, vol. 63, no. 4, pp. 706–712, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Scragg, S. Slow, A. W. Stewart et al., “Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: a randomized controlled trial,” Hypertension, vol. 64, no. 4, pp. 725–730, 2014. View at Google Scholar
  94. E. Schulz, S. Steven, and T. Münzel, “Is at least one vitamin helping our vasculature? Evidence for an important role of the endothelial vitamin d receptor in regulating endothelial function and blood pressure,” Hypertension, vol. 64, no. 6, pp. 1187–1188, 2014. View at Publisher · View at Google Scholar
  95. A. Testa, F. Mallamaci, F. A. Benedetto et al., “Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progressionin end-stage renal disease (ESRD) patients,” Journal of Bone and Mineral Research, vol. 25, no. 2, pp. 313–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. A. M. El-Shehaby, M. M. El-Khatib, S. Marzouk, and A. A. Battah, “Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 73, no. 1, pp. 75–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Santoro, G. Gagliostro, A. Alibrandi et al., “Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease,” Nutrients, vol. 6, no. 3, pp. 1029–1037, 2014. View at Publisher · View at Google Scholar
  98. Y. Solak, A. Covic, and M. Kanbay, “What do we know and do not know about vitamin D? A causal association between vitamin D receptor genetic polymorphism and hypertension,” The Journal of Clinical Hypertension, vol. 16, no. 9, pp. 627–628, 2014. View at Publisher · View at Google Scholar
  99. C. M. Kammerer, A. A. Dualan, P. B. Samollow et al., “Bone mineral density, carotid artery intimal medial thickness, and the vitamin D receptor BsmI polymorphism in Mexican American women,” Calcified Tissue International, vol. 75, no. 4, pp. 292–298, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. E. Kulah, A. Dursun, S. Acikgoz et al., “The relationship of target organ damage and 24-hour ambulatory blood pressure monitoring with vitamin D receptor gene Fok-I polymorphism in essential hypertension,” Kidney and Blood Pressure Research, vol. 29, no. 6, pp. 344–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. N. Swapna, U. Mohana Vamsi, G. Usha, and T. Padma, “Risk conferred by Fokl polymorphism of vitamin D receptor (VDR) gene for essential hypertension,” Indian Journal of Human Genetics, vol. 17, no. 3, pp. 201–206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. L. Wang, J. Ma, J. E. Manson, J. E. Buring, J. M. Gaziano, and H. D. Sesso, “A prospective study of plasma vitamin D metabolites, vitamin D receptor gene polymorphisms, and risk of hypertension in men,” European Journal of Nutrition, vol. 52, no. 7, pp. 1771–1779, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. O. Andrukhova, S. Slavic, U. Zeitz et al., “Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice,” Molecular Endocrinology, vol. 28, no. 1, pp. 53–64, 2014. View at Publisher · View at Google Scholar · View at Scopus